Dosing of phenytoin is difficult in children because of its variable pharmacokinetics and protein binding. Possible covariates for this protein binding have mostly been univariately investigated in small, and often adult, adult populations. We conducted a study to identify and quantify these covariates in children. We extracted data on serum phenytoin concentrations, albumin, triglycerides, urea, total bilirubin and creatinine concentrations and data on coadministration of valproic acid or carbamazepine in 186 children. Using nonlinear mixed effects modeling the effects of covariates on the unbound phenytoin fraction were investigated. Serum albumin, serum urea concentrations, and concomitant valproic acid use significantly influenced the unbound phenytoin fraction. For clinical practice, we recommend that unbound phenytoin concentrations are measured routinely. However, if this is impossible, we suggest to use our model to calculate the unbound concentration. In selected children, close treatment monitoring and dose reductions should be considered to prevent toxicity.
GuerriniR. Epilepsy in children. Lancet. 2006;367:499–524.
2.
PatsalosPNBerryDJBourgeoisBF. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239–1276.
3.
BurtMAndersonDCKlossJAppleFS. Evidence-based implementation of free phenytoin therapeutic drug monitoring. Clin Chem. 2000;46(8 Pt 1):1132–1135.
4.
BanhHLBurtonMESperlingMR. Interpatient and intrapatient variability in phenytoin protein binding. Ther Drug Monit. 2002;24:379–385.
5.
JimenezMCDuranJAAbad InJA. Factors affecting the free plasma fraction of phenytoin in patients with epilepsy. Clin Drug Investig. 1998;15:153–157.
6.
WolfGKMcClainCDZurakowskiDDodsonBMcManusML. Total phenytoin concentrations do not accurately predict free phenytoin concentrations in critically ill children. Pediatr Crit Care Med. 2006;7:434–439.
7.
GriebelMLKearnsGLFiserDHWoodyRCTurleyCP. Phenytoin protein binding in pediatric patients with acute traumatic injury. Crit Care Med. 1990;18:385–391.
8.
StoweCDLeeKRStorgionSAPhelpsSJ. Altered phenytoin pharmacokinetics in children with severe, acute traumatic brain injury. J Clin Pharmacol. 2000;40(12 Pt 2):1452–1461.
9.
DagerWEInciardiJFHoweTL. Estimating phenytoin concentrations by the Sheiner-Tozer method in adults with pronounced hypoalbuminemia. Ann Pharmacother. 1995;29:667–670.
10.
MonaghanMSMarxMAOlsenKMTurnerPDBergmanKL. Correlation and prediction of phenytoin protein binding using standard laboratory parameters in patients after renal transplantation. Ther Drug Monit. 2001;23:263–267.
11.
PattersonMHeazelwoodRSmithurstBEadieMJ. Plasma protein binding of phenytoin in the aged: in vivo studies. Br J Clin Pharmacol. 1982;13:423–425.
12.
BowmerCJLindupWE. Decreased drug binding in uraemia: effect of indoxyl sulphate and other endogenous substances on the binding of drugs and dyes to human albumin. Biochem Pharmacol. 1982;31:319–323.
13.
DasguptaAAbu-AlfaA.Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis. Role of uremic compounds. Am J Clin Pathol. 1992;98:19–25.
14.
DepnerTAGulyassyPF. Plasma protein binding in uremia: extraction and characterization of an inhibitor. Kidney Int. 1980;18:86–94.
15.
KinniburghDWBoydND. Isolation of peptides from uremic plasma that inhibit phenytoin binding to normal plasma proteins. Clin Pharmacol Ther. 1981;30:276–280.
16.
MabuchiHNakahashiH. A major inhibitor of phenytoin binding to serum protein in uremia. Nephron. 1988;48:310–314.
17.
DahlqvistRBorgaORaneAWalshZSjoqvistF. Decreased plasma protein binding of phenytoin in patients on valproic acid. Br J Clin Pharmacol. 1979;8:547–552.
18.
DasguptaACrosseyMJ. Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin. Am J Med Sci. 1997;313:75–79.
19.
HamarCLevyG. Serum protein binding of drugs and bilirubin in newborn infants and their mothers. Clin Pharmacol Ther. 1980;28:58–63.
20.
JoergerMHuitemaADBoogerdWvan der SandeJJSchellensJHBeijnenJH. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic Clin Pharmacol Toxicol. 2006;99:133–140.
21.
KearnsGLKempSFTurleyCPNelsonDL. Protein binding of phenytoin and lidocaine in pediatric patients with type I diabetes mellitus. Dev Pharmacol Ther. 1988;11:14–23.
22.
MayTWRambeckBNothbaumN. Nomogram for the prediction of unbound phenytoin concentrations in patients on a combined treatment of phenytoin and valproic acid. Eur Neurol. 1991;31:57–60.
23.
MilesMVSneadOC IIIThornMD. Predictability of unbound antiepileptic drug concentrations in children treated with valproic acid and phenytoin. Clin Pharm. 1988;7:688–693.
TsanaclisLMAllenJPeruccaERoutledgePARichensA. Effect of valproate on free plasma phenytoin concentrations. Br J Clin Pharmacol. 1984;18:17–20.
26.
ten BergMJHuismanAvan den BemtPMSchobbenAFEgbertsACvan SolingeWW. Linking laboratory and medication data: new opportunities for pharmacoepidemiological research. Clin Chem Lab Med. 2007;45:13–19.
27.
KeizerRJvanBMBeijnenJHSchellensJHHuitemaAD. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101:72–79.
28.
KarlssonMOSheinerLB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21:735–750.
29.
CometsEBrendelKMentreF. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the NPDE add-on package for R. Comput Methods Programs Biomed. 2008;90:154–166.
30.
ItohYEzawaAKikuchiKTsurutaYNiwaT. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem. 2012;403:1841–1850.
31.
VarshneyARehanMSubbaraoNRabbaniGKhanRH. Elimination of endogenous toxin, creatinine from blood plasma depends on albumin conformation: site specific uremic toxicity & impaired drug binding. PLoS One. 2011;6:e17230.
32.
FinneyHNewmanDJThakkarHFellJMPriceCP. Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children. Arch Dis Child. 2000;82:71–75.
33.
ZielinskiJJHaidukewychDLehetaBJ. Carbamazepine-phenytoin interaction: elevation of plasma phenytoin concentrations due to carbamazepine comedication. Ther Drug Monit. 1985;7:51–53.
34.
NikolaosTStylianosGChryssoulaN. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit. 2004;10:MT50–MT52.
